Received for publication June 7, 2003.
Revised July 22, 2003.
Accepted for publication August 29, 2003.

Opioid interactions in rhesus monkeys: Effects of + µ and + agonists on schedule-controlled responding and thermal nociception

Abstract

Delta, mu and kappa opioid agonists produce interacting effects in rodents and non-human primates. To further evaluate the determinants of these interactions, this study examined the effects of mixtures of delta+mu and delta+kappa agonists in rhesus monkeys (n = 4-5) using two behavioral procedures, an assay of schedule- controlled responding for food reinforcement and an assay of thermal nociception. Results were analyzed using dose- addition analysis. In the assay of schedule-controlled responding, the delta agonist SNC80, the mu agonists methadone, fentanyl, morphine and nalbuphine, and the kappa agonists U69,593 and bremazocine all dose- dependently decreased rates of food-maintained responding when administered alone. Fixed ratio mixtures of SNC80+mu agonists produced additive or sub-additive effects, whereas SNC80+kappa agonist mixtures produced only additive effects. In the assay of thermal nociception, SNC80 produced no measurable effects when administered alone, whereas mu and kappa agonists produced dose- dependent antinociception. SNC80+mu agonist mixtures produced super-additive effects manifested as leftward shifts in mu agonist dose-effect curves. This synergism was antagonized by the delta-selective antagonist naltrindole, suggesting that SNC80-induced enhancement of mu agonist antinociception was delta receptor mediated. SNC80 did not enhance the antinociceptive effects of the highly selective kappa agonist U69,593, and it produced only a marginal enhancement of antinociception produced by the less-selective kappa agonist bremazocine. These results suggest that delta agonists may selectively enhance the antinociceptive effects of mu agonists in rhesus monkeys. These results also confirm that opioid agonist interactions may depend on the receptor selectivity and relative doses of the agonists and on the experimental endpoint.

Key words: Rhesus monkey, SNC80, antinociception, interactions, kappa opioid agonists, mu opioid agonists

This article has been cited by other articles:

				G. P. Do Carmo, R. Polt, E. J. Bilsky, K. C. Rice, and S. S. Negus Behavioral Pharmacology of the {micro}/{delta} Opioid Glycopeptide MMP2200 in Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 939 - 948. [Abstract] [Full Text] [PDF]

				Z. D. Cooper, Y. N.-T. Truong, Y.-G. Shi, and J. H. Woods Morphine Deprivation Increases Self-Administration of the Fast- and Short-Acting {micro}-Opioid Receptor Agonist Remifentanil in the Rat J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 920 - 929. [Abstract] [Full Text] [PDF]

				B. D. Fischer and L. A. Dykstra Interactions between an N-Methyl-D-aspartate Antagonist and Low-Efficacy Opioid Receptor Agonists in Assays of Schedule-Controlled Responding and Thermal Nociception J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1300 - 1306. [Abstract] [Full Text] [PDF]

				G. W. Stevenson, J. E. Folk, K. C. Rice, and S. S. Negus Interactions between {delta} and {micro} Opioid Agonists in Assays of Schedule-Controlled Responding, Thermal Nociception, Drug Self-Administration, and Drug versus Food Choice in Rhesus Monkeys: Studies with SNC80 [(+)-4-[({alpha}R)-{alpha}-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and Heroin J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 221 - 231. [Abstract] [Full Text] [PDF]